9 Meters Biopharma Inc
OTC:NMTRQ

Watchlist Manager
9 Meters Biopharma Inc Logo
9 Meters Biopharma Inc
OTC:NMTRQ
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: 1.4k USD

Operating Margin
9 Meters Biopharma Inc

0%
Current
0%
Average
5.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-43.5m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
9 Meters Biopharma Inc
OTC:NMTRQ
1.4k USD N/A
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
526.1B USD
27%
CH
Roche Holding AG
SIX:ROG
277.8B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
217.9B GBP
24%
CH
Novartis AG
SIX:NOVN
221.8B CHF
33%
US
Merck & Co Inc
NYSE:MRK
270.7B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
145.8B USD
29%
No Stocks Found

9 Meters Biopharma Inc
Glance View

Market Cap
1.4k USD
Industry
Pharmaceuticals

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 21 full-time employees. The company went IPO on 2016-07-08. The firm is focused on developing treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs. Its pipeline includes Vurolenatide, Larazotide, NM-102, NM-003, NM-136 and NM-004. Vurolenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that combines exenatide with an extended half-life technology for treatment of short bowel syndrome (SBS). Larazotide is an 8-amino acid peptide formulated into an orally administered capsule for treatment of celiac disease. NM-102 is a small molecule peptide, is being developed as a potential microbiome modulator and is undergoing an indication selection process. NM-003 is a long-acting GLP-2 receptor agonist, for prevention of acute graft versus host disease. NM-004 is a double-cleaved mesalamine with an immunomodulator for pediatric ulcerative colitis.

NMTRQ Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-43.5m
/
Revenue
0
What is the Operating Margin of 9 Meters Biopharma Inc?

Based on 9 Meters Biopharma Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top